Celgene fails to win NICE endorsement for Revlimid

The U.K.'s National Institute for Health and Clinical Excellence ruled that Revlimid, a myeloma drug from Celgene, is not cost effective enough to be covered by the National Health Service. Charitable groups are urging the Department of Health to work with Celgene so that NHS patients can have access to the medicine, which has been shown to prolong the lives of people with the bone marrow cancer by as long as three years.

View Full Article in:

Telegraph (London) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ